ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
60,359.24
-4.27%
S&P 500
5,215.33
0.02%
Dow Jones
39,480.03
0.23%
US Dollar vs Yen
155.806
0.27%
Brent Oil
82.735
-1.45%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Lipocine Inc (LPCN)

  7. Lipocine Inc (LPCN) ニュース

LPCN

Lipocine (LPCN)

Lipocine Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:LPCN
日付受信時刻ニュースソース見出しコード企業名
2024/05/0921 : 00PR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024NASDAQ:LPCNLipocine Inc
2024/05/0919 : 06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
2024/05/0919 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
2024/05/0821 : 00PR Newswire (US)Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024NASDAQ:LPCNLipocine Inc
2024/05/0819 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
2024/05/0121 : 00PR Newswire (US)Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154NASDAQ:LPCNLipocine Inc
2024/04/1120 : 00PR Newswire (US)Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityNASDAQ:LPCNLipocine Inc
2024/03/2821 : 00PR Newswire (US)Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
2024/03/2521 : 00PR Newswire (US)Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
2024/03/0807 : 31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
2024/03/0722 : 00PR Newswire (US)Lipocine Announces Financial Results for the Full Year Ended December 31, 2023NASDAQ:LPCNLipocine Inc
2024/03/0720 : 08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
2024/03/0720 : 07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LPCNLipocine Inc
2024/03/0622 : 00PR Newswire (US)Lipocine to Present at 36th Annual Roth ConferenceNASDAQ:LPCNLipocine Inc
2024/03/0620 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
2024/02/1306 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
2024/02/0622 : 00PR Newswire (US)Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
2024/02/0222 : 00PR Newswire (US)Lipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsNASDAQ:LPCNLipocine Inc
2024/01/1822 : 20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
2024/01/1822 : 00PR Newswire (US)Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaNASDAQ:LPCNLipocine Inc
2023/12/2000 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
2023/12/1922 : 00PR Newswire (US)Lipocine to Present at Biotech Showcase 2024NASDAQ:LPCNLipocine Inc
2023/11/2306 : 15Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LPCNLipocine Inc
2023/11/1404 : 45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
2023/11/1404 : 45PR Newswire (US)Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023NASDAQ:LPCNLipocine Inc
2023/11/0903 : 15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
2023/11/0823 : 50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
2023/11/0822 : 00PR Newswire (US)Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023NASDAQ:LPCNLipocine Inc
2023/11/0122 : 31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
2023/11/0121 : 00PR Newswire (US)Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023NASDAQ:LPCNLipocine Inc
 Showing the most relevant articles for your search:NASDAQ:LPCN

最近閲覧した銘柄

SPI
SP500
S&P 500
AMEX
XLF
Financial Select Sector
CCOM
US100
US Tech 100
CCOM
SILVER
SILVER
COIN
SOLUSD
Solana
CCOM
US500
US 500
USOTC
BNPQY
BNP Paribas (QX)
COIN
BTCUSD
Bitcoin
USOTC
ADDYY
Adidas (QX)
NASDAQ
GOOGL
Alphabet
FX
USDEUR
US Dollar vs Euro
CCOM
US30
US 30
USOTC
RHHBY
Roche (QX)
COIN
ETHUSD
Ethereum
NYSE
MRK
Merck
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有